Skip to main content

Vaccines for the 21st Century A Tool for Decisionmaking (2000) / Chapter Skim
Currently Skimming:

Appendix 25: Streptococcus, Group B
Pages 305-312

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 305...
... Disease Scenarios For the purposes of the calculations in this report, the committee assumed that 90% of GBS disease in neonates is early-onset disease and 20% is late-onset disease. Disease associated with neonatal GBS infections includes bacteremia (86%)
Read the entire page →
From page 306...
... COST INCURRED BY DISEASE Table A25-3 summarizes the health care costs incurred by GBS infections. For the purposes of the calculations in this report, it was assumed that GBS infections in pregnant women are associated with additional hospitalization at the time of delivery and associated inpatient and outpatient physician visits and medication.
Read the entire page →
From page 307...
... outpatient treatment 0.0137 (5 days) NONPREGNANT ADULTS Invasive disease 100.0% soft tissue, bone infection; 0.66 0.052 (19 days)
Read the entire page →
From page 308...
... * LATE ONSET DISEAS~20% of infant cases Bacteremia bacteremia, sepsis, 100% $7,000 pneumonia 1.0 hospitalization NICU 1.0 hospitalization 17.0 physician c 1.0 diagnostic c 365.0 long-term care*
Read the entire page →
From page 309...
... ; additional discounting for immunization interval development of a vaccine for use in pregnant women is discussed within the body of the report. Table 4-1 summarizes vaccine development assumptions for all vaccines considered in this report.
Read the entire page →
From page 310...
... Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 10,200 for 90% utilization by pregnant women and 4,500 for 10% utilization by pregnant women. If a vaccine program for group B streptococci were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $630 million.
Read the entire page →
From page 311...
... Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 6,200. If a vaccine program for group B streptococci were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $435 million.
Read the entire page →
From page 312...
... Farley MM. A Population-Based Assessment of Invasive Disease Due to Group B Streptococcus in Nonpregnant Adults.
Read the entire page →

Key Terms

  • pregnant women
  • committee assumptions
  • using committee
  • target population
  • including time

  • monetary costs
  • nonpregnant adults
  • care costs
  • gbs infections
  • qalys gained

  • qaly gained
  • costs saved
  • life expectancy
  • committee assumed
  • vaccine development

  • program cost
  • annual immunization
  • gbs disease
  • physician visits
  • adjusted life

  • inpatient physician
  • involves annual
  • gbs experience
  • acute care
  • fixed cost

  • summarizes vaccine
  • invasive disease
  • streptococci vaccine
  • vaccines considered
  • require hospitalization


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.